Citigroup’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Citigroup’s Portfolio SXTP Stock Details SXTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$2	–	6230
2026 Q1	$2	Buy	+1	New	+$3	﹤0.01%	5836
2025 Q4	–	Sell	-47	Closed	-$278	–	6464
2025 Q3	$278	Buy	+47	New	+$286	﹤0.01%	5746

Other funds holding SXTP

KCM

Kathmere Capital Management Wayne, Pennsylvania $1.89B AUM 26.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Citigroup's SXTP Position: Q2 2026 in Review

Citigroup sold out of 60 Degrees Pharmaceuticals (SXTP) in Q2 2026, closing a stake of 1 share — an estimated $2 sold.

Citigroup first reported a position in SXTP in Q3 2025 and held it in 2 quarters. The position peaked at $278 in Q3 2025. 8 funds tracked by Wall St. Rank hold SXTP as of Q2 2026.

Citigroup reported no remaining 60 Degrees Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Citigroup sold 1 60 Degrees Pharmaceuticals share in Q2 2026, an estimated $2.
Citigroup first reported a position in 60 Degrees Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Citigroup's 60 Degrees Pharmaceuticals position peaked at $278 in Q3 2025.
8 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.